Determination of the optimal therapeutic protocols in cancer immunotherapy

被引:44
作者
Cappuccio, Antonio [1 ]
Castiglione, Filippo [1 ]
Piccoli, Benedetto [1 ]
机构
[1] CNR, Ist Applicaz Calcolo, I-00161 Rome, Italy
关键词
optimization; protocol design; immunotherapy; cancer; drug holidays;
D O I
10.1016/j.mbs.2007.02.009
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer immunotherapy alms at eliciting an immune system response against the tumor. However, it is often characterized by toxic side-effects. Limiting the tumor growth and, concurrently, avoiding the toxicity of a drug, is the problem of protocol design. We formulate this question as an optimization problem and derive an algorithm for its solution. Unlike the standard optimal control approach, the algorithm simulates impulse-like drug administrations. It relies on an exact computation of the gradient of the cost function with respect to any protocol by means of the variational equations, that can be solved in parallel with the system. In comparison with previous versions of this method [F. Castiglione, B. Piccoli, Optimal control in a model of dendritic cell transfection cancer immunotherapy, Bull. Math. Biol. 68 (2006) 255; B. Piccoli, F. Castiglione, Optimal vaccine scheduling in cancer immunotherapy, Physica A. 370 (2) (2007) 672], we optimize both the timing and the dosage of each administration and introduce a penalty term to avoid clustering of subsequent injections, a requirement consistent with the clinical practice. In addition, we implement the optimization scheme to simulate the case of multitherapies. The procedure works for any ODE system describing the pharmacokinetics and pharmacodynamics of an arbitrary number of therapeutic agents. In this work, it was tested for a well known model of the tumor-immune system interaction [D. Kirschner, J.C. Panetta, Modeling immunotherapy of turnor-immune interaction, J. Math. Biol. 37 (1998) 2351. Exploring three immunotherapeutic scenarios (CTL therapy, IL-2 therapy and combined therapy), we display the stability and efficacy of the optimization method, obtaining protocols that are successful compromises between various clinical requirements. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 13 条
[1]  
BenEfraim S, 1996, ANTICANCER RES, V16, P3235
[2]   THE RELATIONSHIP OF BLOOD-TRANSFUSION, TUMOR STAGING, AND CANCER RECURRENCE [J].
BLUMBERG, N ;
CHUANGSTEIN, C ;
HEAL, JM .
TRANSFUSION, 1990, 30 (04) :291-294
[3]  
Burden T, 2004, DISCRETE CONT DYN-B, V4, P135
[4]  
CASTIGLIONE, IN PRESS
[5]   Optimal control in a model of dendritic cell transfection cancer immunotherapy [J].
Castiglione, F ;
Piccoli, B .
BULLETIN OF MATHEMATICAL BIOLOGY, 2006, 68 (02) :255-274
[6]   CYCLIC LEUKOCYTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA - NEW PERSPECTIVES ON PATHOGENESIS AND THERAPY [J].
GATTI, RA ;
ROBINSON, WA ;
DEINARD, AS ;
NESBIT, M ;
MCCULLOUGH, JJ ;
BALLOW, M ;
GOOD, RA .
BLOOD, 1973, 41 (06) :771-782
[7]   A PROSPECTIVE RANDOMIZED STUDY OF PROPHYLAXIS OF TUMOR RECURRENCE FOLLOWING TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER-CANCER - INTRAVESICAL THIO-TEPA VERSUS ORAL UFT [J].
HIRAO, Y ;
OKAJIMA, E ;
OZONO, S ;
SAMMA, S ;
SASAKI, K ;
HIRAMATSU, T ;
BABAYA, K ;
WATANABE, S ;
MARUYAMA, Y .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 :S26-S30
[8]   CYCLIC LEUKOCYTE OSCILLATIONS IN CHRONIC MYELOGENOUS LEUKEMIA DURING HYDROXYUREA THERAPY [J].
KENNEDY, BJ .
BLOOD-THE JOURNAL OF HEMATOLOGY, 1970, 35 (06) :751-&
[9]   Modeling immunotherapy of the tumor-immune interaction [J].
Kirschner, D ;
Panetta, JC .
JOURNAL OF MATHEMATICAL BIOLOGY, 1998, 37 (03) :235-252
[10]   OPTIMAL-CONTROL DRUG SCHEDULING OF CANCER-CHEMOTHERAPY [J].
MARTIN, RB .
AUTOMATICA, 1992, 28 (06) :1113-1123